Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
--Poster to be Presented at 2017 ACR/ARHP Annual Meeting--
“These preclinical studies suggest our ALPN-101 program vIgDs can
potently reduce pathogenic T cell activation, inflammatory cytokines,
and disease activity in multiple inflammatory diseases,” said
The immunoglobulin superfamily (IgSF) is a large, diverse family of proteins expressed on immune cells and collectively plays critical roles in immune regulation. Well-known IgSF proteins include PD-1, PD-L1, CTLA-4, CD28, CD80/CD86 (B7-1/2), inducible T cell costimulator (
In contrast, Alpine’s vIgD platform transforms natural IgSF proteins
into multifunctional protein domains. CD28 and
Evaluations included a mouse model of inflammatory arthritis and a
humanized mouse model of GvHD. Belatacept, an immunosuppressive T-cell
co-stimulation blocker approved by the
Preclinical Study Results
Presented data from the ICOSL vIgD-Fcs:
- Inhibited multiple parameters of disease in inflammatory arthritis including reducing paw swelling, inflammatory cell infiltrates, circulating inflammatory cytokines, anti-collagen autoantibodies, and lymph node follicular helper T cells, B cells, and activated T cells.
- Prolonged survival and reduced disease activity in GvHD.
- Appeared superior to abatacept in arthritis based on clinical scores and histology, and to belatacept in GvHD based on disease activity scores and survival.
“We are encouraged by the preclinical data generated to date. The vIgD
platform can produce novel, potent IgSF-based immuno-modulators whose
efficacy has the potential to exceed existing approved therapies,” said
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact, and include statements regarding Alpine’s platform technology, potential therapies and the potential efficacy of such therapies. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: Alpine’s discovery-stage and pre-clinical programs may not advance into the clinic or result in approved products on a timely or cost-effective basis or at all; Alpine may not achieve additional milestone payments pursuant to its collaborations; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in Alpine’s filings with the
“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,”
“vIgD,” and the Alpine logo are registered trademarks or trademarks of